XTL Biopharmaceuticals Ltd. (XTLB)
2.53
-0.25
(-8.99%)
USD |
NASDAQ |
Aug 24, 16:00
2.53
0.00 (0.00%)
After-Hours: 20:00
XTL Biopharmaceuticals Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2024 | -88.23% |
| September 30, 2024 | -341.3% |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 |
| Date | Value |
|---|---|
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | -197.9% |
| June 30, 2014 | -186.8% |
| March 31, 2014 | -129.6% |
| December 31, 2013 | -254.9% |
| September 30, 2013 | 94.08% |
| June 30, 2013 | -243.0% |
| March 31, 2013 | -163.7% |
| December 31, 2012 | -92.10% |
| September 30, 2012 | -43.73% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| BioLineRx Ltd. | -542.6% |
| Kamada Ltd. | 16.86% |
| Can-Fite BioPharma Ltd. | -- |
| Galmed Pharmaceuticals Ltd. | -- |
| Revium Recovery, Inc. | -- |